Targeting a specific receptor in aggressive brain tumors with radiation therapy
IL13Ra2-targeted radioimmunotherapy for glioblastoma
['FUNDING_R21'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11139747
This study is testing a new treatment that uses targeted radiation to attack glioblastoma cells, aiming to help patients by reducing damage to healthy tissue and improving their chances of recovery.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11139747 on ClinicalTrials.gov |
What this research studies
This research focuses on using radioimmunotherapy to target the IL13Rα2 receptor, which is commonly found on glioblastoma cells. By delivering radiation specifically to these cancer cells, the treatment aims to minimize damage to surrounding healthy tissues. The approach utilizes beta-emitting isotopes that can effectively kill tumor cells, even those that are resistant to traditional therapies. Patients with glioblastoma may benefit from this targeted treatment, which seeks to improve outcomes and reduce recurrence rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who express the IL13Rα2 receptor.
Not a fit: Patients with glioblastoma who do not express the IL13Rα2 receptor or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with radioimmunotherapy targeting specific receptors in various cancers, indicating potential for success in this novel application.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KREBS, SIMONE — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: KREBS, SIMONE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Radiation Syndrome